BIIB

Biogen

$253.40

+1.17%
Nov 13, 2026
Bobby Quantitative Model
Biogen is a biopharmaceutical company focused on neuroscience and rare diseases, with a portfolio spanning a legacy multiple sclerosis franchise (Fumarate, Interferon, TYSABRI), the Spinraza spinal muscular atrophy drug, the Leqembi Alzheimer's collaboration with Eisai, and newer assets like Skyclarys, Zurzuvae, and Qalsody. It is an established, mid-cap drug developer rather than a high-growth disruptor, and its identity is increasingly defined by the tension between a structurally declining MS base business (roughly 40% of revenue) and a bet on a new wave of neuro and immunology assets. The current investor narrative centers on whether the strategic pivot is finally gaining traction: Q2 2026 results beat expectations and management raised revenue guidance, and the company has been deploying capital into early-stage immunology via the up-to-$1 billion RayThera acquisition. That optimism is tempered by episodic clinical setbacks, including a 2026 Alzheimer's trial miss that triggered a sharp selloff, so the debate is fundamentally about pipeline execution risk versus a cheap, cash-generative base.

People also watch

Eli Lilly and Company

Eli Lilly and Company

LLY

Analysis
Johnson & Johnson

Johnson & Johnson

JNJ

Analysis
AbbVie

AbbVie

ABBV

Analysis
Merck & Co.

Merck & Co.

MRK

Analysis
Amgen

Amgen

AMGN

Analysis

BobbyInvestment Opinion: Should I buy BIIB Today?

Rating: Hold, with a constructive bias toward accumulating on weakness. The core thesis is that Biogen is a cash-generative, cheaply valued neuroscience franchise (15.27x forward PE, 1.41x book, ~9.1% FCF yield on $2.34 billion TTM FCF) whose 58.45% one-year run has already captured most of the near-term re-rating, leaving only ~7.3% upside to the $266.39 average target despite a 25-Buy/10-Hold/1-Sell consensus and a 1.78 recommendation mean. In other words, the business quality and analyst conviction support owning the stock, but the current $248.35 entry point offers an unattractive near-term risk/reward for new money.

Supporting evidence is genuinely strong on fundamentals: Q3 2026 revenue of $2.804 billion grew 14.23% YoY and has climbed sequentially from $2.478 billion in Q1 to $2.736 billion in Q2, gross margin is 73.31%, and the balance sheet carries only 0.38 debt-to-equity with a 2.68 current ratio. Valuation is undemanding — 19.89x trailing PE, 2.63x PS, 10.10x EV/EBITDA versus the 15-20x norm for profitable large-cap biopharma, and a PS ratio compressed from 15.71x in Q4 2023 to 2.63x today. The catch is earnings quality: Q3 swung to a $20.6 million net loss (EPS -$0.14) as $574 million of R&D and $752 million of G&A overwhelmed $128.4 million of operating income, and the bottom line has been negative in two of the last four quarters.

The biggest risks that could invalidate the thesis are (1) a second major pipeline failure — a Leqembi commercialization shortfall or a RayThera immunology disappointment — which would break the revenue re-acceleration narrative and push analysts toward the $175 low target (~-30% from $248.35); (2) faster-than-expected erosion of the legacy MS franchise, which still contributes roughly 40% of revenue alongside 19% Roche CD20 collaboration concentration; and (3) simple valuation compression given the stock sits just 4.0% below its $258.78 high with thin ~1.0 million share daily volume and a 4.46 short ratio amplifying gap risk. This Hold would upgrade to Buy on a pullback toward the $220-$225 consolidation zone (implying roughly 15-18% upside to consensus) or on evidence that Leqembi and immunology revenue are scaling faster than MS declines; it would downgrade to Sell on a break below that support zone or a forward EPS revision below the $21.08 consensus. Net verdict: fairly valued to modestly undervalued on cash flow and book value, but no longer cheap on momentum — a value opportunity for patient holders rather than a fresh-entry bargain.

Sign up to view all

BIIB 12-Month Price Forecast

The forward view is balanced: Biogen's fundamentals are improving (14.23% revenue growth, 73.31% gross margin, $2.34 billion TTM FCF, 0.38 debt-to-equity) and its 15.27x forward PE and 1.41x book are cheap versus history and peers, but the 58.45% one-year rally has already closed most of the gap to the $266.39 consensus, leaving a modest ~7.3% implied return. The 25-Buy/10-Hold/1-Sell consensus and the $175-to-$350 target spread capture the real debate — conviction in the cash-generative base business, uncertainty in pipeline execution after the 2026 Alzheimer's miss. I would upgrade to bullish on a pullback toward the $220-$225 support zone or on hard evidence that Leqembi and immunology revenue are outpacing MS erosion, and downgrade to bearish if a second clinical disappointment hits or the stock breaks below that support with volume.

Historical Price
Current Price $253.40
Average Target $267.50
High Target $350.00
Low Target $175.00

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Biogen's 12-month outlook, with a consensus price target around $268.26 and implied upside of +5.9% versus the current price.

Average Target

$268.26

36 analysts

Implied Upside

+5.9%

vs. current price

Analyst Count

36

covering this stock

Price Range

$175 - $350

Analyst target range

Buy
25 (69%)
Hold
10 (28%)
Sell
1 (3%)

Coverage is broad and decisively bullish. Thirty-two analysts cover Biogen, with 25 Buy ratings, 10 Hold, and just 1 Sell, producing a consensus recommendation of "buy" and a recommendation mean of 1.78 (where 1.0 is a strong buy). The average target price is $266.39, implying roughly 7.3% upside from the current $248.35, a modest gap that suggests much of the near-term optimism is already priced in after the 58% one-year run. The consensus leans clearly bullish on direction but implies limited immediate upside.

The target range is wide, from $175 to $350, signaling meaningful disagreement about the pipeline's value. The $350 high target implies multiple expansion and successful commercialization of Leqembi and the immunology pipeline, while the $175 low target discounts continued MS erosion and clinical disappointment. Recent institutional activity is constructive: Argus upgraded from Hold to Buy on October 29, and Guggenheim, HC Wainwright, TD Cowen, Canaccord, RBC, UBS, and Truist all reiterated Buy or Outperform ratings around the Q3 print, with only Morgan Stanley and Wedbush staying neutral. That pattern of reiterations plus one upgrade, against a wide target spread, points to strong conviction on the base business with residual uncertainty concentrated in pipeline execution.

Drowning in data?

Find the real signal!

Bulls vs Bears: BIIB Investment Factors

The bull case currently has stronger evidence: revenue is genuinely re-accelerating at 14.23% YoY, the balance sheet is fortress-like with 0.38 debt-to-equity and a 2.68 current ratio, free cash flow yields roughly 9.1%, and 25 of 32 analysts rate the stock Buy with a $266.39 average target. The bear case rests less on the financials than on the price — after a 58.45% one-year run the stock sits 4.0% below its high with only ~7.3% implied upside to consensus, and Q3's $20.6 million net loss shows how quickly R&D and G&A can erase a 73.31% gross margin. The single most important tension is whether the new franchises can scale fast enough to offset a legacy MS base still contributing roughly 40% of revenue; if Leqembi and the immunology pipeline deliver, the 15.27x forward PE and 1.41x book re-rate meaningfully, but if pipeline execution disappoints again as it did in the 2026 Alzheimer's miss, the 'cheap' multiple is a value trap. Near term, the debate is less about business quality than about how much of the turnaround is already in the price.

Bullish

  • Revenue re-accelerating at 14.2% YoY: Q3 2026 revenue of $2.804 billion grew 14.23% year-over-year, extending a sequential climb from $2.478 billion in Q1 to $2.736 billion in Q2. This is the clearest evidence yet that newer franchises and collaboration revenue are outrunning the structural decline of the legacy MS base, which is the central test of the pivot thesis.
  • Deep value multiples versus history: The stock trades at 19.89x trailing PE, 15.27x forward PE, 2.63x PS, 1.41x book, and 10.10x EV/EBITDA — well below the 15-20x EV/EBITDA norm for profitable large-cap biopharma. The PS ratio has compressed from 15.71x in Q4 2023 to 2.63x today, placing the stock near the low end of its own valuation band.
  • 9.1% free cash flow yield funds the pivot: TTM free cash flow of $2.34 billion against a $25.8 billion market cap implies roughly a 9.1% FCF yield. The company repaid $400 million of debt in Q3 from $640.8 million of operating cash flow while growing cash to $1.304 billion, so pipeline investment and bolt-on M&A like the up-to-$1 billion RayThera deal need no external financing.
  • Analyst consensus decisively bullish: Of 32 analysts, 25 rate Buy, 10 Hold, and only 1 Sell, producing a recommendation mean of 1.78 and a consensus of 'buy.' The average target of $266.39 implies about 7.3% upside, and Argus upgraded to Buy on October 29 while Guggenheim, HC Wainwright, TD Cowen, Canaccord, RBC, UBS, and Truist all reiterated Buy or Outperform around the Q3 print.

Bearish

  • Bottom line is lumpy and just turned negative: Q3 2026 posted a net loss of $20.6 million (EPS -$0.14) despite a 73.31% gross margin, as $574 million of R&D and $752 million of G&A plus $137.4 million of net other expenses swamped $128.4 million of operating income. The quarterly swing is extreme — from $319.5 million of net income in Q1 to $97.5 million in Q2 to a loss in Q3 — and Q4 2025 also lost $48.4 million.
  • MS franchise still ~40% of revenue and eroding: MS product revenue of $919.3 million plus TYSABRI at $437.1 million, Fumarate at $274.0 million, and Interferon at $208.2 million keeps the legacy base the largest revenue generator at roughly 40% of the total. Growth must permanently outrun this decline, and the CD20 Roche collaboration adds another 19% concentration in a single partner relationship.
  • Pipeline execution risk is proven, not theoretical: A 2026 Alzheimer's trial miss triggered a sharp selloff, and the $1 billion RayThera acquisition is a milestone-driven bet on an undisclosed early-stage immunology asset whose value depends entirely on future clinical success. With a $175-to-$350 analyst target spread, the market is explicitly pricing wide disagreement about pipeline value.
  • Near-term upside largely priced in: At $248.35 versus an average target of $266.39, the implied upside is only about 7.3% after a 58% one-year run. The stock sits at roughly 90% of its 52-week range, so the risk/reward is asymmetric to the downside if momentum stalls or a catalyst disappoints.

BIIB Technical Analysis

Biogen is in a powerful, sustained uptrend. The stock is up 58.45% over the past year and 39.66% year-to-date, and at $248.35 it sits at roughly 90% of its 52-week range (low $153.77, high $258.78), just 4.0% below the high. That positioning signals strong momentum rather than a value opportunity, though proximity to the highs also raises the risk of overextension and profit-taking. The move has decisively outperformed the market: relative strength versus SPY is +48.86% over one year and +31.83% YTD, a level of leadership that typically reflects a fundamental re-rating rather than a simple beta-driven rally.

Short-term momentum is accelerating and confirms the longer-term trend rather than diverging from it. The stock gained 11.79% in the past month, 19.43% over three months, and 28.38% over six months, meaning each successive window is positive and the most recent month is the strongest. Critically, this occurred while SPY fell 4.99% over the same month, producing a +16.78% relative-strength spread, which is the signature of idiosyncratic, catalyst-driven demand. The one caution is the reported beta of 0.086, which is implausibly low for a biotech and likely a data artifact; the more meaningful volatility signal is the 14.34% max drawdown, indicating the stock can still correct sharply on news.

Key technical levels are well defined. Resistance sits at the 52-week high of $258.78, and a breakout above that level on volume would confirm the uptrend and likely open a new leg higher. Support is anchored by the 52-week low of $153.77, with intermediate support likely around the $220-$225 area where the stock consolidated in September and early October before its late-October surge. A breakdown below that zone would signal the momentum trade is unwinding. Given the elevated short ratio of 4.46 days-to-cover and thin daily volume of roughly 1.0 million shares, moves in either direction can be amplified, so position sizing should account for gap risk around clinical and earnings catalysts.

Beta

0.09

0.09x market volatility

Max Drawdown

-14.3%

Largest decline past year

52-Week Range

$160-$261

Price range past year

Annual Return

+53.8%

Cumulative gain past year

PeriodBIIB ReturnS&P 500
1m+8.8%-2.3%
3m+20.8%-2.8%
6m+31.3%+2.1%
1y+53.8%+12.3%
ytd+42.5%+10.6%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

BIIB Fundamental Analysis

The revenue trajectory has turned positive after a period of stagnation. Q3 2026 revenue was $2.804 billion, up 14.23% year-over-year, and the sequential progression from $2.478 billion in Q1 to $2.736 billion in Q2 to $2.804 billion in Q3 shows steady acceleration. The segment mix remains concentrated in legacy MS, with MS product revenues of $919.3 million, TYSABRI at $437.1 million, Fumarate at $274.0 million, and Interferon at $208.2 million, while Spinraza contributed $460.6 million. The growth is therefore being driven by newer franchises and collaboration revenue offsetting MS erosion, which is the key test of whether the pivot can outrun the decline of the base business.

Profitability is lumpy and currently under pressure at the bottom line. Q3 2026 net income was a loss of $20.6 million (EPS -$0.14) despite a healthy 73.31% gross margin and $2.056 billion in gross profit, as $574 million of R&D and $752 million of G&A plus $137.4 million of net other expenses overwhelmed operating income of $128.4 million. The quarterly pattern is volatile: Q1 delivered $319.5 million of net income (EPS $2.15) and Q2 $97.5 million (EPS $0.66), while Q4 2025 lost $48.4 million. Trailing net margin is 13.18% and operating margin 19.14%, respectable for large-cap pharma but well below the 2025 quarterly peaks, reflecting elevated R&D investment in the pipeline.

The balance sheet is solid and the cash engine is the core of the investment case. Debt-to-equity is a modest 0.38, the current ratio is a strong 2.68, and TTM free cash flow is $2.34 billion against a $25.8 billion market cap, implying an FCF yield of roughly 9.1%. ROE of 7.08% and ROA of 4.94% are modest, dragged down by the Q3 loss, but the company funded $400 million of debt repayment in Q3 from operating cash flow of $640.8 million while still growing cash to $1.304 billion. This internally funded model means Biogen does not depend on external financing to support its pipeline or bolt-on M&A.

Quarterly Revenue

$2.8B

2026-09

Revenue YoY Growth

+14.2%

YoY Comparison

Gross Margin

73.3%

Latest Quarter

Free Cash Flow

$2.1B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Fumarate
Interferon
MS Product Revenues
SPINRAZA
TYSABRI product

Open an Account, get $2 TSLA now!

Valuation Analysis: Is BIIB Overvalued?

Because trailing net income is positive on a TTM basis, the PE ratio is the appropriate primary metric, and it tells a nuanced story. The trailing PE is 19.89x while the forward PE is 15.27x, a roughly 23% compression that implies the market expects meaningful earnings growth ahead, consistent with consensus EPS of $21.08 versus the current trailing figure of about $0.05 per share on a distorted basis. The PEG ratio of -0.95 is not meaningful given the negative growth denominator and should be disregarded.

On peer comparison, Biogen screens cheap relative to its own history and to large-cap pharma norms. The PS ratio of 2.63x and EV/Sales of 4.20x are modest for a company with a 70.47% gross margin, and EV/EBITDA of 10.10x is well below the 15-20x range typical of profitable large-cap biopharma. The price-to-book of 1.41x is a clear discount to the sector, reflecting skepticism about the durability of the MS franchise rather than any balance-sheet weakness. The discount looks justified only if pipeline assets fail to offset MS erosion; if Leqembi and the immunology bets scale, the multiple has room to re-rate.

Historical context reinforces the point. Biogen's PS ratio has compressed from 15.71x in Q4 2023 and 13.69x in mid-2024 to 2.63x today, and its PE has ranged from single digits (7.2x in Q2 2025) to over 80x on depressed earnings. The stock is therefore near the low end of its own valuation band on sales, which historically has marked either deep value or fundamental deterioration. Given the improving revenue growth and strong FCF, the current 19.89x trailing PE and 1.41x book look more like a value opportunity than a warning sign, though the market is clearly not yet paying for the pipeline.

PE

19.9x

Latest Quarter

vs. Historical

Mid-Range

5-Year PE Range 7x~38x

vs. Industry Avg

18.6x

Industry PE ~18.6x*

EV/EBITDA

10.1x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on earnings volatility and revenue concentration rather than solvency. Q3 2026 swung to a $20.6 million net loss (EPS -$0.14) from $319.5 million of net income in Q1, with $574 million of R&D and $752 million of G&A consuming a 73.31% gross margin and leaving only $128.4 million of operating income; Q4 2025 also lost $48.4 million, so the bottom line has been negative in two of the last four quarters. The legacy MS franchise (MS products $919.3 million, TYSABRI $437.1 million, Fumarate $274.0 million, Interferon $208.2 million) plus the Roche CD20 collaboration at 19% of 2025 revenue means roughly 59% of the business sits in two declining or partner-dependent buckets. The offsetting strength is a 0.38 debt-to-equity ratio, a 2.68 current ratio, and $2.34 billion of TTM free cash flow, which means the risk is to the multiple and the growth trajectory, not to the balance sheet.

Market and competitive risks are dominated by valuation compression and pipeline binary outcomes. The stock has run 58.45% in a year and 39.66% YTD to $248.35, just 4.0% below its $258.78 high, leaving only ~7.3% upside to the $266.39 consensus target — a setup where good news is largely discounted. The $175-to-$350 target spread and the 2026 Alzheimer's trial miss show how violently a single clinical readout can reprice the shares, and the RayThera immunology bet is a milestone-driven $1 billion commitment to an undisclosed asset. Competitive pressure is intensifying: AbbVie's FDA approval of the Parkinson's pill Juvmo strengthens a direct neuroscience rival, while peers such as Denali are showing rapid uptake in adjacent neuro categories. The reported 0.086 beta is a data artifact and should be ignored; the more honest volatility gauge is the 14.34% max drawdown, and thin volume of ~1.0 million shares with a 4.46 short ratio amplifies gap risk around catalysts.

In a worst-case scenario, a second major pipeline failure — for example, a Leqembi commercialization shortfall or a RayThera immunology disappointment — would combine with accelerating MS erosion to break the revenue re-acceleration narrative, forcing analysts toward the $175 low target and a de-rating of the 15.27x forward PE toward the low end of its historical band. From $248.35, a move to the $175 analyst low target implies roughly -30%, and a retest of the $153.77 52-week low would imply about -38%. A realistic adverse path is a -25% to -38% drawdown over 12 months, consistent with the stock's demonstrated ability to gap sharply on clinical news and its current position near the top of its range.

FAQ

The most severe risk is pipeline execution: a second clinical or commercial disappointment, following the 2026 Alzheimer's trial miss, would break the revenue re-acceleration narrative and could push shares toward the $175 analyst low target, roughly -30% from $248.35. Second is revenue concentration — the legacy MS franchise (MS products $919.3 million, TYSABRI $437.1 million, Fumarate $274.0 million, Interferon $208.2 million) is still about 40% of revenue and structurally declining, while the Roche CD20 collaboration adds another 19% partner concentration. Third is earnings volatility: Q3 2026 swung to a $20.6 million net loss (EPS -$0.14) as $574 million of R&D and $752 million of G&A overwhelmed $128.4 million of operating income, and the bottom line has been negative in two of the last four quarters. Fourth is valuation and liquidity risk — after a 58.45% run the stock sits 4.0% below its high with thin ~1.0 million share daily volume and a 4.46 short ratio that can amplify gap moves; the reported 0.086 beta is a data artifact and understates true volatility, with the 14.34% max drawdown a better gauge.

The scenario framework assigns a 50% probability to the base case of $255-$280, a 25% probability to the bull case of $300-$350, and a 25% probability to the bear case of $175-$200. The base case is most likely: revenue growth moderates into the high single digits to low double digits, gross margin holds near 70%, free cash flow stays around $2.3 billion, and the stock drifts toward the $266.39 analyst average target — about 7% above the current $248.35 — without meaningful multiple expansion. The bull case requires Leqembi uptake to accelerate, a positive early signal from the RayThera immunology asset, and MS erosion to flatten enough that 14%+ growth proves durable, re-rating the 15.27x forward PE toward the 20x+ large-cap norm and reaching the $350 high target. The bear case assumes a second pipeline failure plus accelerating MS decline, pushing shares toward the $175 low target, with a retest of the $153.77 52-week low implying about -38%. The key assumption behind the base case is that no major binary event forces a re-rating in either direction.

On fundamentals the stock screens modestly undervalued. It trades at 19.89x trailing PE but only 15.27x forward PE, implying roughly 23% earnings growth is expected, consistent with the $21.08 consensus forward EPS. EV/EBITDA of 10.10x and price-to-book of 1.41x sit well below the 15-20x EV/EBITDA range typical of profitable large-cap biopharma, and the PS ratio of 2.63x has compressed dramatically from 15.71x in Q4 2023. The market is therefore paying a discount that reflects skepticism about the durability of the ~40%-of-revenue MS franchise and lingering doubt after the 2026 Alzheimer's trial miss. On momentum, however, the stock is no longer cheap: after a 58.45% one-year gain it sits at roughly 90% of its 52-week range with only ~7.3% upside to the $266.39 consensus. The verdict is fairly valued to modestly undervalued on cash flow and book value, but fully priced on near-term momentum — the market is not yet paying for the pipeline, which is the upside optionality.

The risk/reward is mixed at the current $248.35. On the positive side, 25 of 32 analysts rate the stock Buy with a 1.78 recommendation mean, the average target of $266.39 implies about 7.3% upside, and the valuation is undemanding at 15.27x forward PE, 1.41x book, and 10.10x EV/EBITDA against roughly $2.34 billion of TTM free cash flow. The downside is that the stock has already rallied 58.45% over one year and sits just 4.0% below its $258.78 high, so most of the near-term re-rating appears captured. The biggest risk is a second pipeline failure — a Leqembi shortfall or RayThera disappointment — which could drive shares toward the $175 analyst low, roughly -30%. It is a reasonable buy for value-oriented investors with a multi-year horizon who can tolerate clinical binary risk, and a poor entry for short-term traders chasing momentum; accumulating on a pullback toward the $220-$225 support zone materially improves the setup.

Biogen is better suited to a long-term hold than to short-term trading. The company is in a mid-stage strategic pivot — a declining MS base being offset by Leqembi, Spinraza, Skyclarys, and the up-to-$1 billion RayThera immunology bet — and that transition will take multiple quarters to prove out, so a minimum holding period of 18-24 months is appropriate to let pipeline catalysts and revenue mix shift play out. The stock pays no dividend (0% yield, 0% payout ratio), so total return depends entirely on earnings growth and multiple re-rating rather than income. Earnings visibility is limited and lumpy — EPS has ranged from -$0.33 in Q4 2025 to $2.15 in Q1 2026 — and binary clinical readouts can gap the stock sharply, which argues against leveraged or short-horizon positioning. Short-term traders should note the stock is extended after a 58.45% one-year run, just 4.0% below its high, with thin ~1.0 million share volume and a 4.46 short ratio; the $220-$225 support zone and the $258.78 resistance level are the key tactical markers.